|
LSG1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.61380028732106E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.31690000307827E-09 |
| Normal-vs-Stage2 |
2.936900E-03 |
| Normal-vs-Stage3 |
1.39389999542772E-09 |
| Normal-vs-Stage4 |
1.27460042520511E-10 |
| Stage1-vs-Stage2 |
8.350200E-02 |
| Stage1-vs-Stage3 |
1.404420E-01 |
| Stage1-vs-Stage4 |
2.300200E-02 |
| Stage2-vs-Stage3 |
1.301690E-02 |
| Stage2-vs-Stage4 |
3.035800E-03 |
| Stage3-vs-Stage4 |
4.491800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06940001298739E-09 |
| Normal-vs-AfricanAmerican |
3.767100E-04 |
| Normal-vs-Asian |
1.26540000000563E-06 |
| Caucasian-vs-AfricanAmerican |
7.571400E-01 |
| Caucasian-vs-Asian |
9.008600E-01 |
| AfricanAmerican-vs-Asian |
8.390400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.8414999483154E-09 |
| Normal-vs-Female |
9.28189969329196E-10 |
| Male-vs-Female |
6.024000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.60829946319552E-10 |
| Normal-vs-Age(41-60Yrs) |
4.5874000043078E-08 |
| Normal-vs-Age(61-80Yrs) |
8.69109999523943E-08 |
| Normal-vs-Age(81-100Yrs) |
1.955310E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.281600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.061800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.386400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.612800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.396400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.969200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.760230E-02 |
| Classical-VS-Follicular |
9.304200E-01 |
| Classical-VS-Other |
4.991600E-01 |
| Classical-VS-Normal |
4.29059998641179E-09 |
| Tall-VS-Follicular |
1.996220E-02 |
| Tall-VS-Other |
7.004800E-01 |
| Tall-VS-Normal |
6.92559998238806E-09 |
| Follicular-VS-Other |
5.693200E-01 |
| Follicular-VS-Normal |
2.15139999999447E-05 |
| Other-VS-Normal |
6.820900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.29840000551962E-08 |
| Normal-vs-N1 |
3.88230003700585E-10 |
| N0-vs-N1 |
5.838300E-03 |
|
|
